MYELOMA NEWS
NINLARO NOW APPROVED BY HEALTH CANADA
IMPORTANT NEWS!
NEW MYELOMA DRUG APPROVED BY HEALTH CANADA
Myeloma Canada is pleased to share the important news that on August 8th 2016, Takeda Canada received approval from Health Canada for NINLARO™ (ixazomib) in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. NINLARO™ is the first and only oral proteasome inhibitor, and the approval makes a new option available to meet the urgent needs of patients living with relapsed and/or refractory multiple myeloma.
Click here for the link to the Takeda Canada news release.
Ninlaro will have to undergo reviews by the pan Canadian Oncology Drug Review (pCODR) and the pan Canadian Pharmaceutical Alliance (pCPA) processes before it can be listed on provincial drug formularies. Myeloma Canada is committed to working diligently with myeloma support groups and patient advocates across the country to ensure this new and innovative treatment is made available to patients across the country in a timely manner.
Walk the Walk. Make Myeloma Matter.
Click on one of the 12 cities below to sign up or donate to the